Immatics N.V Stock, NASDAQ:IMTX
Paul-Ehrlich-Strasse 15, Tuebingen, Baden Wuerttemberg 72076
Number of Employees: 198
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The firm's clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCERâ„¢). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.